Safety, Immunogenicity and Efficacy of NVX-CoV2373 in Adolescents in PREVENT-19: A Randomized, Phase 3 Trial

Germán Áñez, Lisa M. Dunkle, Cynthia L. Gay, Karen L. Kotloff, Jeffrey M. Adelglass, Brandon Essink, James D. Campbell, Shane Cloney-Clark, Mingzhu Zhu, Joyce S. Plested, Pavitra Roychoudhury, Alexander L. Greninger, Nita Patel, Alice McGarry, Wayne Woo, Iksung Cho, Gregory M. Glenn, Filip Dubovsky, the 2019nCoV-301 – Pediatric Expansion Study Group
doi: https://doi.org/10.1101/2022.09.20.22279903

Data Availability

A data-sharing statement provided by the authors will be available with the full text of this article upon publication (https://clinicaltrials.gov/ct2/show/NCT04611802).

https://clinicaltrials.gov/ct2/show/NCT04611802

Back to top
Posted September 21, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Safety, Immunogenicity and Efficacy of NVX-CoV2373 in Adolescents in PREVENT-19: A Randomized, Phase 3 Trial
Germán Áñez, Lisa M. Dunkle, Cynthia L. Gay, Karen L. Kotloff, Jeffrey M. Adelglass, Brandon Essink, James D. Campbell, Shane Cloney-Clark, Mingzhu Zhu, Joyce S. Plested, Pavitra Roychoudhury, Alexander L. Greninger, Nita Patel, Alice McGarry, Wayne Woo, Iksung Cho, Gregory M. Glenn, Filip Dubovsky, the 2019nCoV-301 – Pediatric Expansion Study Group
medRxiv 2022.09.20.22279903; doi: https://doi.org/10.1101/2022.09.20.22279903
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area